Tariq Musa sold $20K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $175.00 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Sep 17, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting no immediate price pressure.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases could outweigh the impact of this minor sale.

Relevance 2/10Novelty 4/10Timing: post‑market 2026-09-16

Background

Form 4 filings disclose insider transactions; directors often use 10b5‑1 plans to avoid timing concerns.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Director Tariq Musa sold 116 shares of Guardant Health for $20.3K on 2026-09-16 via a 10b5‑1 plan.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to market cap and disclosed via a pre‑arranged plan, indicating no urgent market signal.

Market effects

None; insider sale does not affect broader biotech sector.

None; limited to Guardant Health shareholders.

None; no global market effect.

Counterpoint

Some investors may view any insider selling as a negative signal, but the small amount and pre‑arranged plan mitigate concern.

Key entities

  • Guardant Health, Inc.

    US‑listed liquid biopsy company (NASDAQ: GH).

  • Tariq Musa

    Director of Guardant Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.